A Phase I/II Study of CP-4055 in Patients With Platinum Resistant Ovarian Cancer.
Latest Information Update: 16 Sep 2013
At a glance
- Drugs Elacytarabine (Primary)
- Indications Ovarian cancer
- Focus Adverse reactions; Therapeutic Use
- 03 Sep 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 03 Sep 2010 Actual end date (Apr 2010) added as reported by ClinicalTrials.gov.
- 17 Dec 2009 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.